Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
Date:5/3/2011

oking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.Lexicon Pharmaceuticals, Inc.Selected Financial DataConsolidated Statements of Operations DataThree Months EndedMarch 31,(In thousands, except per share data)20112010(unaudited)Revenues:Collaborative research$  516$  1,641Subscription and license fees80-Total revenues5961,641Operating expenses:Research and development, inclu
'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Lexicon to Provide First Quarter 2011 Financial Results
2. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
3. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
5. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
6. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
7. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
8. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
9. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
10. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
11. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Medina ... as CEO and member of the Board of Directors ... of medical device development and commercialization experience, including over ... Mr. Engelson previously served as a Partner of the ... President and CEO of two Foundry start-ups. Mr. Engelson ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... , August 29, 2014 ... Seed Oil Market by Extraction type (SFE, Cold ... & Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) ... by MarketsandMarkets, defines and segments the Amaranth Seed ... the market size in terms of value. The ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2China Orthopedic Instrument Industry Report, 2014-2017 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4
... Sept. 21, 2011 Reportlinker.com announces that a ... catalogue: Generic Drugs: The ... http://www.reportlinker.com/p0619264/Generic-Drugs-The-Global-Market-Focus-on-the-Americas.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment ... examination of the strategies employed by companies specializing ...
... SAN DIEGO, Sept. 20, 2011 Orexigen® Therapeutics, Inc. ... a recent meeting with senior officials in FDA,s Office ... detailing OND,s design requirements for a cardiovascular outcomes trial ... Letter (CRL) received in January 2011. Orexigen believes that ...
Cached Medicine Technology:Generic Drugs: The Global Market: Focus on the Americas 2Generic Drugs: The Global Market: Focus on the Americas 3Generic Drugs: The Global Market: Focus on the Americas 4Generic Drugs: The Global Market: Focus on the Americas 5Generic Drugs: The Global Market: Focus on the Americas 6Generic Drugs: The Global Market: Focus on the Americas 7Generic Drugs: The Global Market: Focus on the Americas 8Generic Drugs: The Global Market: Focus on the Americas 9Generic Drugs: The Global Market: Focus on the Americas 10Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 2Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 3Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 4Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 5
(Date:8/29/2014)... According to a CNN article, entitled Medical ... new study found that those states who legalized medical ... decrease in the number of painkiller overdoses seen. By ... and comparing various states with and without legalized medical ... about a 25% decrease in painkiller prescription overdoses in ...
(Date:8/29/2014)... 2014 As reported by the Frederick News Post ... Grad (8/17), a graduate of the Frederick County Drug Treatment ... own experience with the program. The graduate, Korey Shorb, put together ... 1 mile walk. He plans to donate the proceeds of the ... those who helped him. Shorb, who graduated in 2008, admitted that ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe has ... will give patients the convenience of visiting with physicians ... doctors through telemedicine. , Healthpointe doctors are always available ... audio). If necessary, the doctor can even see the ... patient’s condition, he or she can prescribe medications that ...
(Date:8/29/2014)... News) -- Astronauts may be at heightened risk ... immune systems, a new study suggests. That could ... asteroids, the moon and Mars undertaken in the future, ... can be dangerous, NASA researchers say. They found ... of International Space Station crew members remains relatively unchanged ...
(Date:8/29/2014)... 2014 (HealthDay News) -- If you have bunions, taking care ... later, an expert says. A bunion is a bump ... bone or tissue moves out of place and extends beyond ... cause debilitating pain and may require surgery to correct, said ... Center in Freehold, N.J. To prevent bunions, avoid wearing ...
Breaking Medicine News(10 mins):Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 3Health News:Drug Court Grad Brings More Life to Drug Court Program 2Health News:Drug Court Grad Brings More Life to Drug Court Program 3Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:Take Steps to Control Bunions 2
... Diluted Share, LARGO, Fla., May 28 ... Exchange: UVI), which develops,licenses, manufactures, distributes and markets ... the third quarter and first nine,months of FY2008., ... quarter ended March 31,2008 increased to $1,668,397 compared ...
... 2008 - You went to a wedding yesterday. The service ... dancing all night. But people tell you that you are ... and that you didnt go to a wedding yesterday at ... following neurological damage is known as confabulation. The reasons why ...
... new vegetarian food that boosts the uptake of iron and ... the result of a doctoral dissertation by Charlotte Eklund-Jonsson at ... Sweden. , The food, called tempe, is moreover a whole-grain ... in medicine that whole-grains reduce the risk of cardiovascular diseases, ...
... Hainan, China, May 28 /Xinhua-PRNewswire-FirstCall/ --,China Pharma ... Bulletin,Board: CPHI) which develops, manufactures, and markets ... announced that it has entered,into a Securities ... institutional and accredited investors ("Investors") pursuant to ...
... access to insurance tend to have healthier children , , WEDNESDAY, ... care in America varies widely from state to state, ... likelihood of living long and healthy lives. , That,s the ... a private foundation that seeks to promote better health care ...
... advantage of quick and,easy travel to the beautiful ... Conference: Leadership Development - Finding, Growing & Retaining,Top ... ), sponsored by Best Practices,LLC,s GLOBAL BENCHMARKING ... Fla., Registration ends this week so sign ...
Cached Medicine News:Health News:Unilens Vision Reports Increased Royalty Income 2Health News:Unilens Vision Reports Increased Royalty Income 3Health News:Unilens Vision Reports Increased Royalty Income 4Health News:China Pharma Holdings, Inc. Enters Into Private Placement Agreements to Raise $10 Million 2Health News:China Pharma Holdings, Inc. Enters Into Private Placement Agreements to Raise $10 Million 3Health News:States' Scorecard Finds Big Differences in Kids' Health Care 2Health News:States' Scorecard Finds Big Differences in Kids' Health Care 3Health News:Registration Ends This Week: Fortune 500 Networking & Best Practice Sharing Conference in Florida 2
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: